- Lonafarnib
- Pegylated Interferon Lambda
- Avexitide
The Hutchinson-Gilford Progeria Syndrome and Progeroid Laminopathy Managed Access Program
Eiger BioPharmaceuticals, the distributor of the drug lonafarnib, is sponsoring a Managed Access Program (MAP) for eligible patients with Hutchinson-Gilford Progeria Syndrome (HGPS or Progeria) or a Progeroid Laminopathy (PL). The protocol governing this program can be viewed at ClinicalTrials.gov. The MAP study number is NCT03895528. Clinigen is the administrator of the lonafarnib MAP for HGPS and PL.
Patients or family members desiring more information about this program should speak to their doctors or contact The Progeria Research Foundation at 978-535-2594 or e-mail info@progeriaresearch.org. Patients and family members should not contact Clinigen. Clinigen is only authorized to speak with doctors.
For treating doctors with questions about the MAP, please contact Clinigen’s Medicine Access Team at +44 (0) 1932 824123 or email medicineaccess@clinigengroup.com. The doctor may also e-mail Eiger at ProgeriaMA@eigerbio.com or Eigeraccess@eigerbio.com.
Eiger BioPharmaceuticals Announces First COVID-19 Patients Dosed with Peginterferon Lambda - Approximately 120 patients with mild COVID-19 at the Stanford University School of Medicine will be randomized 1:1 to a single subcutaneous dose of Lambda or normal saline placebo to evaluate the efficacy of Lambda in reducing the duration of viral shedding of SARS-CoV-2 virus and in reducing duration of symptoms and hospitalization in patients with mild COVID-19. Patients will be followed for 28 days.